10.55
price up icon2.73%   0.28
after-market After Hours: 10.55
loading
Abivax Adr stock is traded at $10.55, with a volume of 33,187. It is up +2.73% in the last 24 hours and up +7.87% over the past month. Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
See More
Previous Close:
$10.27
Open:
$10.41
24h Volume:
33,187
Relative Volume:
0.28
Market Cap:
$654.34M
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-105.22M
1W Performance:
-1.31%
1M Performance:
+7.87%
6M Performance:
-27.44%
1Y Performance:
+4.46%
1-Day Range:
Value
$10.25
$11.02
1-Week Range:
Value
$10.21
$11.02
52-Week Range:
Value
$8.75
$17.02

Abivax Adr Stock (ABVX) Company Profile

Name
Name
Abivax Adr
Name
Phone
-
Name
Address
-
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ABVX's Discussions on Twitter

Abivax Adr Stock (ABVX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-14-23 Initiated Leerink Partners Outperform
Nov-14-23 Initiated Morgan Stanley Equal-Weight

Abivax Adr Stock (ABVX) Latest News

pulisher
Oct 15, 2024

Check Out Abivax ADR (ABVX)’s Trade Data Rather Than the Analysts’ Views - SETE News

Oct 15, 2024
pulisher
Oct 15, 2024

Insider’s View: Deciphering Abivax ADR (ABVX)’s Financial Health Through Ratios - The Dwinnex

Oct 15, 2024
pulisher
Oct 07, 2024

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewswire Inc.

Oct 07, 2024
pulisher
Sep 26, 2024

Abivax SA Unveils New Ulcerative Colitis Treatment Data - TipRanks

Sep 26, 2024
pulisher
Sep 25, 2024

Abivax Reports Progress in Ulcerative Colitis Therapy - TipRanks

Sep 25, 2024
pulisher
Sep 16, 2024

DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire

Sep 16, 2024
pulisher
Sep 14, 2024

Wall Street Analysts Believe Abivax SA Sponsored ADR (ABVX) Could Rally 193.62%: Here's is How to Trade - MSN

Sep 14, 2024
pulisher
Sep 13, 2024

Is Abivax SA Sponsored ADR (ABVX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Sep 13, 2024
pulisher
Sep 09, 2024

Abivax SA Details Financial Struggles and Advances - TipRanks

Sep 09, 2024
pulisher
Sep 09, 2024

Abivax SA Reveals Soaring R&D Costs in H1 2024 - TipRanks

Sep 09, 2024
pulisher
Jul 15, 2024

Inflammatory Bowel Disease Treatment Market Size Expected to Reach USD 33.19 Bn by 2032 - GlobeNewswire Inc.

Jul 15, 2024
pulisher
Jun 04, 2024

Abivax SA Advances with Positive Trial OutcomesTipRanks.com - TipRanks

Jun 04, 2024
pulisher
May 07, 2024

Abivax SA Announces Upcoming General MeetingTipRanks.com - TipRanks

May 07, 2024
pulisher
Apr 29, 2024

Guggenheim starts Abivax stock with Buy, cites promising ulcerative colitis drug By Investing.com - Investing.com

Apr 29, 2024
pulisher
Apr 02, 2024

Abivax SA Secures Funding and Expands Operations - TipRanks

Apr 02, 2024
pulisher
Oct 26, 2023

Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire

Oct 26, 2023

Abivax Adr Stock (ABVX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
Cap:     |  Volume (24h):